Page 1

INTERIM REPORT January - June 2026 SYNACTOPHARMA Research and development in inflammatory diseases This English version of SynAct Pharma's Interim Report for the second quarter of 2026 has been prepared by the Company as a service to its non - Swedish stakeholders . In case of differences , the original Swedish report prevails . www.synactpharma.com Q2